Literature DB >> 17557176

Mammary tumor modifiers in BALB/cJ mice heterozygous for p53.

Joanna G Koch1, Xiangjun Gu, Younghun Han, Adel K El-Naggar, Melissa V Olson, Daniel Medina, D Joseph Jerry, Anneke C Blackburn, Gary Peltz, Christopher I Amos, Guillermina Lozano.   

Abstract

BALB/c mice are predisposed to developing spontaneous mammary tumors, which are further increased in a p53 heterozygous state. C57BL/6J mice are resistant to induced mammary tumors and develop less than 1% mammary tumors in both wild-type and p53+/- states. To map modifiers of mammary tumorigenesis, we have established F1 and F2 crosses and backcrosses to BALB/cJ (N2-BALB/cJ) and C57BL/6J (N2-C57BL/6J) strains. All cohorts developed mammary carcinomas in p53+/- females, suggesting that multiple loci dominantly and recessively contributed to mammary tumorigenesis. We mapped two modifiers of mammary tumorigenesis in the BALB/cJ strain. Mtsm1 (mammary tumor susceptibility modifier), a dominant-acting modifier, is located on chromosome 7. Mtsm1 is suggestive for linkage to mammary tumorigenesis (p = 0.001). We have analyzed the Mtsm1 region to locate candidate genes by comparing it to a rat modifier region, Mcs3, which shares syntenic conservation with Mtsm1. Expression data and SNPs were also taken into account. Five potential candidate genes within Mtsm1 are Aldh1a3, Chd2, Nipa2, Pcsk6, and Tubgcp5. The second modifier mapped is Mtsm2, a recessive-acting modifier. Mtsm2 is located on chromosome X and is significantly linked to mammary tumorigenesis (p = 1.03 x 10(-7)).

Entities:  

Mesh:

Year:  2007        PMID: 17557176     DOI: 10.1007/s00335-007-9028-2

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  30 in total

1.  GCP5 and GCP6: two new members of the human gamma-tubulin complex.

Authors:  S M Murphy; A M Preble; U K Patel; K L O'Connell; D P Dias; M Moritz; D Agard; J T Stults; T Stearns
Journal:  Mol Biol Cell       Date:  2001-11       Impact factor: 4.138

2.  Genetic identification of multiple loci that control breast cancer susceptibility in the rat.

Authors:  L A Shepel; H Lan; J D Haag; G M Brasic; M E Gheen; J S Simon; P Hoff; M A Newton; M N Gould
Journal:  Genetics       Date:  1998-05       Impact factor: 4.562

Review 3.  The Li-Fraumeni syndrome: an inherited susceptibility to cancer.

Authors:  S C Evans; G Lozano
Journal:  Mol Med Today       Date:  1997-09

4.  Pro-protein convertase gene expression in human breast cancer.

Authors:  M Cheng; P H Watson; J A Paterson; N Seidah; M Chrétien; R P Shiu
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

5.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  Cancer incidence and mortality, 1973-1995: a report card for the U.S.

Authors:  P A Wingo; L A Ries; H M Rosenberg; D S Miller; B K Edwards
Journal:  Cancer       Date:  1998-03-15       Impact factor: 6.860

7.  Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells.

Authors:  B N Rexer; W L Zheng; D E Ong
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 8.  The genetics and genomics of cancer.

Authors:  Allan Balmain; Joe Gray; Bruce Ponder
Journal:  Nat Genet       Date:  2003-03       Impact factor: 38.330

9.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

10.  Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.

Authors:  Tomoo Iwakuma; John M Parant; Mark Fasulo; Edwin Zwart; Tyler Jacks; Annemieke de Vries; Guillermina Lozano
Journal:  Oncogene       Date:  2004-10-07       Impact factor: 9.867

View more
  24 in total

1.  Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes.

Authors:  Angelica R Harper; Anh T Le; Timothy Mather; Anthony Burgett; William Berry; Jody A Summers
Journal:  Bioorg Med Chem       Date:  2018-10-24       Impact factor: 3.641

2.  Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Authors:  Shunbin Xiong; Huolin Tu; Madhusudhan Kollareddy; Vinod Pant; Qin Li; Yun Zhang; James G Jackson; Young-Ah Suh; Ana C Elizondo-Fraire; Peirong Yang; Gilda Chau; Mehrnoosh Tashakori; Amanda R Wasylishen; Zhenlin Ju; Hilla Solomon; Varda Rotter; Bin Liu; Adel K El-Naggar; Lawrence A Donehower; Luis Alfonso Martinez; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

3.  SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability.

Authors:  Y Wang; S Klumpp; H M Amin; H Liang; J Li; Z Estrov; P Zweidler-McKay; S J Brandt; A Agulnick; L Nagarajan
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

4.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Authors:  Shunbin Xiong; Vinod Pant; Yun Zhang; Neeraj K Aryal; M James You; Donna Kusewitt; Guillermina Lozano
Journal:  J Pathol       Date:  2017-01-06       Impact factor: 7.996

Review 5.  The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.

Authors:  Alea A Mills
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 6.  Physiological insights into all-trans-retinoic acid biosynthesis.

Authors:  Joseph L Napoli
Journal:  Biochim Biophys Acta       Date:  2011-05-19

7.  Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Authors:  Edgar S Díaz-Cruz; Priscilla A Furth
Journal:  Cancer Res       Date:  2010-05-15       Impact factor: 12.701

8.  A unified 35-gene signature for both subtype classification and survival prediction in diffuse large B-cell lymphomas.

Authors:  Yu-Dong Cai; Tao Huang; Kai-Yan Feng; Lele Hu; Lu Xie
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

Review 9.  Mammary cancer susceptibility: human genes and rodent models.

Authors:  Claude Szpirer; Josiane Szpirer
Journal:  Mamm Genome       Date:  2007-12-01       Impact factor: 2.957

Review 10.  Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily.

Authors:  Satori A Marchitti; Chad Brocker; Dimitrios Stagos; Vasilis Vasiliou
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-06       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.